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Copyright © 200? JCBN Summary Mulberry leaves are rich in 1-deoxynojirimycin (DNJ), an inhibitor of α-glucosidase.
We previously showed that DNJ-rich mulberry leaf extract suppressed elevation of postprandial
blood glucose in humans. The objective of this study was to evaluate the effects of DNJ-rich
mulberry leaf extract on plasma lipid profiles in humans. An open-label, single-group study
was conducted in 10 subjects with initial serum triglyceride (TG) level ≥200 mg/dl. Subjects
ingested capsules containing DNJ-rich mulberry leaf extract at 12 mg three times daily before
meals for 12 weeks. Our findings showed a modest decrease in serum TG level and beneficial
changes in the lipoprotein profile following 12-week administration of DNJ-rich mulberry leaf
extract. No significant changes in hematological or biochemical parameters were observed
during the study period; no adverse events associated with DNJ-rich mulberry leaf extract
occurred.
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Introduction
Intake of food from animal sources, especially those with
a higher ratio of lipid energy, increases risk of hyperlipemia,
which, in turn may cause arteriosclerosis and even myo-
cardial infarction and cerebral infarction in the long run. It is
therefore very important to endeavor to control serum lipids
in daily life.
Mulberry (Morus alba L. and other plants of the genus
Morus) has traditionally been cultivated in China, Korea,
and Japan to use its leaves to feed silkworms (Bombyx mori
L.) or as Chinese herbal tea based on folklore. In the
modern era, health benefits from mulberry products have
been scientifically verified, and naturally occurring 1-
deoxynojirimycin (DNJ), a kind of azasugar, was first
isolated from its roots by Yagi et al. [1] in 1976. DNJ is a
glucose analogue with a secondary amine group instead of
an oxygen atom in the pyranose ring of glucose. DNJ
potently inhibits α-glucosidase in the small intestine by
binding to the active center of α-glucosidase [2]. More
recently, DNJ has also been found in the leaves and fruits of
M. alba [3, 4], suggesting that the legendary antidiabetic
effect of mulberry leaves may be attributed to DNJ, which
inhibits postprandial hyperglycemia [2, 4] by inhibiting α-
glucosidase in the small intestine. Since then, the preventive
effect of mulberry leaves on diabetes has been extensively
studied. There have been findings from animal studies sup-Y. Kojima et al.
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porting the hypothesis that mulberry leaves delay the onset
of diabetes, as indicated by the fact that a rapid increase in
the postprandial blood glucose level was inhibited [5–7].
We have established a new assay method of DNJ in
mulberry leaves [8–10] and developed a method for culti-
vating and processing mulberry leaves as well as food
containing DNJ-rich mulberry leaves [11]. A study of the
mulberry leaf food was conducted in healthy and marginally
diabetic subjects, showing that it inhibited postprandial
increases in the blood glucose and insulin levels [11]. In a
long-term treatment study, intake of mulberry leaf DNJ was
not associated with abnormalities [11]. A study in rats
showed that DNJ and mulberry leaf extract increased the
serum adiponectin level and stimulated AMP-activated
protein kinase to activate the β-oxidation and thereby inhibit
lipid accumulation in the liver [12]. The present study was
designed to evaluate the effect of the mulberry extract on
serum lipids in humans with relatively high triglyceride
(TG) level.
Materials and Methods
Study design
To evaluate the effect of DNJ-rich mulberry leaf extract
on serum lipids in humans, a 12-week long-term treatment
study was conducted in subjects with relatively high serum
TG level (≥200 mg/dl). This was an open-label study
designed to carry out investigations before the start of the
intake of test food and at weeks 6 and 12. The pretreatment
tests were performed twice, and the results from the second
test (performed ~2 weeks before the start of the investiga-
tion) were regarded as the baseline levels. The study was
conducted from January to June 2008. After being reviewed
and approved by the institutional review board of the
Medical Corporation Nishi Iin (Osaka, Japan), the study
was conducted in the Medical Corporation Kenshokai
Kinki Kenshin Center (Osaka, Japan). It was conducted in
accordance with the Declaration of Helsinki (as revised in
Tokyo 2004), the Ethical Guidelines for Epidemiological
Research (Notification No. 1 of Ministry of Education,
Culture, Sports, Science and Technology/Ministry of Health,
Labour and Welfare, 2004), and the study protocol.
DNJ-rich mulberry leaf extract
The DNJ-rich mulberry leaf extract was provided in an
aluminum pouch packed with 3 hard capsules containing
12 mg of DNJ in total (supplied by Minato Pharmaceutical
Co., Ltd., Tokyo, Japan). The extract was given at a dose of
3 capsules three times daily before each meal (9 capsules,
equivalent to 36 mg of DNJ, per day) for 12 weeks. Three
capsules of the test food contained 5.1 kcal of energy, 0.29 g
of protein, 0 g of lipid, 0.97 g of carbohydrate, and 0.44 mg
of sodium.
The dose of the test food was determined based on the
data from the previous investigations. Briefly, after the
intake of mulberry leaf extract or placebo, post-sucrose
challenge blood glucose was measured in healthy subjects.
By the intake of mulberry leaf extract equivalent to 12 or
18 mg of DNJ, the increase in blood glucose was signifi-
cantly suppressed 30 and 60 min after the administration of
sucrose (50 g) [11], suggesting that the single effective dose
of mulberry leaf extract may be equivalent to 12 mg of
DNJ. In addition, there were no adverse effects in a 38-day
continuous treatment study, in which mulberry leaf extract at
a DNJ dose of 18 mg three times daily (equivalent to 54 mg
of DNJ per day) was given to healthy subjects [11].
Subjects
Subjects were recruited in accordance with the regulations
of the Site Management Organization to enroll those who
met all of the inclusion criteria and none of the exclusion
criteria. The inclusion criteria were as follows: males
between 20 and 64 years of age; Japanese nationality; and
serum TG level ≥200 mg/dl. The exclusion criteria were as
follows: regular use of pharmaceutical product(s) and/or
specified health food to improve serum TG; allergy to
study-related food or drug; participation in another clinical
study or trial at the start of the present study; continuous
pharmacotherapy for any disease; and considered by the
investigator to be ineligible for the study based on the
laboratory values, etc. As a result, 10 subjects were included
in the study. Subjects were instructed to confirm the intake
of test food and record any subjective symptom and treat-
ment with pharmaceutical product(s) in a diary, which was
used in an interview by a physician for reference.
Test parameters
Alcohol intake was restricted from two days prior to the
tests, and no foods or beverages were allowed from the end
of dinner on the day before tests to the completion of tests.
On each test day, blood and urine were collected in the
morning.
In hematologic tests, white blood cell count, red blood
cell count, hematocrit, and platelet count were measured. In
blood biochemical tests, total TG, chylomicron (CM)-TG,
very low density lipoprotein (VLDL)-TG, total cholesterol,
low density lipoprotein (LDL)-cholesterol, high density
lipoprotein (HDL)-cholesterol, aspartate amino transferase
(AST), alanine amino transferase (ALT), lactate dehydro-
genase (LDH), alkaline phosphatase (ALP), γ-glutamyl
transpeptidase (γ-GTP), total bilirubin, albumin, total protein,
blood urea nitrogen, creatinine, blood glucose, insulin,
hemoglobin, hemoglobin A1c, Na, K, and Cl were measured.
In special tests, adiponectin, leptin, apolipoprotein B (ApoB),
and lipoprotein fractions were measured [13–15]. In
urinalysis, protein and glucose were measured. PlasmaBlood Lipid Profiles after Mulberry Leaf Extract Intake
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lipoproteins were separated to 20 fractions according to
the particle size [CM (2 fractions), large VLDL (3 fractions),
medium VLDL, small VLDL, large LDL, medium LDL,
small LDL, very small LDL (3 fractions), very large HDL
(2 fractions), large HDL, medium HDL, small HDL, and
very small HDL (2 fractions)]. Of the 20 fractions, the level
of cholesterol in LDL fractions was assessed according to
the sub-class particle size: large, medium, small, and very
small. In addition, the mean particle size of VLDL, LDL,
and HDL was calculated from the particle size of each of
the 20 fractions.
Statistical analysis
All test values are expressed as mean ± standard devia-
tion. For each parameter, 1-sample t test was performed to
compare the value at week 6 or 12 with the baseline value
(obtained from the second pretreatment test). No multi-
plicity was taken into consideration. All statistical analyses
were performed at a two-sided significance level of 5%.
Results
Subject characteristics
Subject characteristics are shown in Table 1. All subjects
were male, with an age of 43.6 ± 7.7 years, a baseline body
weight of 79.2 ± 10.8 kg, and a body mass index (BMI) of
28.0 ± 3.7. During intake of test food, no significant change
was observed in systolic or diastolic blood pressure or pulse
rate, with good compliance as shown by a mean intake rate
of 95.7%. No deviation from the protocol was noted.
Analysis population
At week 6, a blood sample from 1 subject was chylous.
Also at reexamination performed 1 week later, the blood
sample from the same subject was chylous. At the discretion
of the investigator, this subject was excluded from the
efficacy analysis because the chylous samples were not
appropriate for measurement of serum lipids.
Efficacy evaluation
Changes in serum TG and cholesterol over time.   The changes
in serum TG and cholesterol over time are shown in Table 2.
The mean serum TG level decreased from 312 ± 90 mg/dl
at baseline to 269 ± 66 mg/dl at week 6 and to 252 ± 78
mg/dl at week 12, but the differences were not statistically
significant (week 6, p = 0.200; week 12, p = 0.058). There
was also no significant change from baseline at week 6 or 12
in total cholesterol, LDL-cholesterol, or HDL-cholesterol.
Lipoprotein fractions. The changes in CM-TG and VLDL-
TG over time are shown in Table 3. The mean CM-TG level
was 9.0 ± 5.6 mg/dl at week 12, significantly decreased
from baseline (18.6 ± 9.1 mg/dl) (p = 0.031). At week 6,
it was 10.5 ± 6.8 mg/dl, decreased from baseline, but with
no significant difference (p = 0.068). The mean VLDL-TG
level was 139.6 ± 45.9 mg/dl at week 12, increased from
baseline (110.3 ± 23.3 mg/dl), but with no significant
difference (p = 0.089). At week 6, it was 162.7 ± 46.7 mg/dl,
significantly increased from baseline (p =0 . 0 0 7 ) .
The changes in blood LDL-cholesterol level over time
according to the particle size are shown in Table 4. The
Table 1. Subject characteristics
Mean ± SD (n = 10). No significant difference was observed, compared with week 0.
Parameter Unit
Baseline 
(Week 0)
Week 6 Week 12
Height cm 168.3 ± 5.8 — —
Body weight kg 79.2 ± 10.8 78.1 ± 10.5 77.1 ± 11.0
BMI kg/m2 28.0 ± 3.7 27.6 ± 3.4 27.2 ± 3.5
Systolic blood pressure mmHg 129 ± 19 128 ± 15 131 ± 14
Diastolic blood pressure mmHg 84 ± 13 82 ± 11 81 ± 12
Pulse rate beat/min 85 ± 15 77 ± 10 79 ± 12
Table 2. Changes in serum TG and cholesterol over time
Mean ± SD (n = 9). No significant difference was observed, compared with week 0.
Parameter Reference range Unit
Baseline 
(Week 0)
Week 6 Week 12
Serum TG 30~149 mg/dl 312 ± 90 269 ± 66 252 ± 78
Total cholesterol 130~220 mg/dl 232 ± 25 243 ± 20 230 ± 21
LDL-cholesterol 70~139 mg/dl 139 ± 32 149 ± 25 145 ± 23
HDL-cholesterol 40~90 mg/dl 42 ± 64 4 ± 64 3 ± 5Y. Kojima et al.
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mean blood level of large LDL-cholesterol was 20.7 ± 4.7
mg/dl at week 12, significantly increased from baseline
(18.1 ± 5.2 mg/dl) (p = 0.047). At week 6, it was 22.2 ± 5.6
mg/dl, increased from baseline, but with no significant
difference (p = 0.055). The mean blood level of medium
LDL-cholesterol was 42.4 ± 10.3 and 43.4 ± 9.3 mg/dl at
weeks 6 and 12, respectively, significantly increased from
baseline (32.8 ± 8.9 mg/dl) (p<0.001 at both weeks 6 and
12). The mean blood level of small LDL-cholesterol was
34.7 ± 7.3 and 36.2 ± 6.9 mg/dl at weeks 6 and 12, respec-
tively, significantly increased from baseline (28.7 ± 7.1
mg/dl) (p = 0.005 at both weeks 12 and 6). The mean blood
level of very small LDL-cholesterol was 16.0 ± 2.7 and
16.9 ± 3.4 mg/dl at weeks 6 and 12, respectively, signifi-
cantly decreased from baseline (21.0 ± 4.4 mg/dl) (week 12,
p = 0.039; week 6, p =0 . 0 0 5 ) .
The changes in the mean particle size of VLDL, LDL, and
HDL over time are shown in Table 5. The mean particle size
of VLDL was 45.92 ± 1.42 and 45.87 ± 1.19 nm at weeks 6
and 12, respectively, significantly decreased from baseline
(47.03 ± 0.91 nm) (week 6, p = 0.049; week 12, p =0 . 0 0 3 ) .
The mean particle size of LDL was 24.58 ± 0.29 and
24.48 ± 0.29 nm at weeks 6 and 12, respectively, signifi-
cantly increased from baseline (24.12 ± 0.38 nm) (week 6,
p = 0.007; week 12, p = 0.014). The mean particle size of
HDL was 10.54 ± 0.19 nm at week 12, significantly increased
from baseline (10.40 ± 0.18 nm) (p = 0.006). At week 6,
it was 10.51 ± 0.13 nm, increasing from baseline, but with
no significant difference (p = 0.056).
Changes in adiponectin, leptin, and ApoB over time. The
changes in adiponectin, leptin, and ApoB over time are
shown in Table 6. The mean adiponectin level was 4.9 ± 1.5
and 4.6 ± 1.4 μg/ml at weeks 6 and 12, respectively,
significantly decreased from baseline (6.3 ± 2.1 μg/ml)
(p = 0.001 at both weeks 6 and 12). The mean leptin level
was 5.2 ± 3.9 and 4.7 ± 4.4 ng/ml at weeks 6 and 12, respec-
Table 3. Changes in CM-TG and VLDL-TG over time
Mean ± SD (n =9 ) .  *  p<0.05, ** p<0.01, compared with week 0.
Parameter Unit
Baseline 
(Week 0)
Week 6 Week 12
CM-TG mg/dl 18.6 ± 9.1 10.5 ± 6.8 9.0 ± 5.6*
VLDL-TG mg/dl 110.3 ± 23.3 162.7 ± 46.7** 139.6 ± 45.9
Table 4. Changes in the blood LDL-cholesterol level over time according to the particle size
Mean ± SD (n =9 ) .  *  p<0.05, ** p<0.01, compared with week 0. Numbers in parentheses represent percent distribution
among the for LDL subfractions.
Parameter Unit
Baseline 
(Week 0)
Week 6 Week 12
Large LDL mg/dl 18.1 ± 5.2 
(18.0 ± 3.7)
22.2 ± 5.6 
(19.4 ± 4.1)
20.7 ± 4.7* 
(17.7 ± 3.0)
Medium LDL mg/dl 32.8 ± 8.9 
(32.3 ± 2.8)
42.4 ± 10.3** 
(36.4 ± 2.5**)
43.4 ± 9.3** 
(36.8 ± 2.7**)
Small LDL mg/dl 28.7 ± 7.1 
(28.5 ± 2.5)
34.7 ± 7.3** 
(30.1 ± 3.0)
36.2 ± 6.9** 
(31.0 ± 2.7*)
Very small LDL mg/dl 21.0 ± 4.4 
(21.2 ± 3.8)
16.0 ± 2.7** 
(14.1 ± 2.2**)
16.9 ± 3.4* 
(14.5 ± 2.6**)
Table 5. Changes in the mean particle size of VLDL, LDL, and HDL over time
Mean ± SD (n =9 ) .  *  p<0.05, ** p<0.01, compared with week 0.
Parameter Unit
Baseline 
(Week 0)
Week 6 Week 12
VLDL nm 47.03 ± 0.91 45.92 ± 1.42* 45.87 ± 1.19**
LDL nm 24.12 ± 0.38 24.58 ± 0.29** 24.48 ± 0.29*
HDL nm 10.40 ± 0.18 10.51 ± 0.13 10.54 ± 0.19**Blood Lipid Profiles after Mulberry Leaf Extract Intake
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tively, significantly decreased from baseline (6.3 ± 4.1 ng/ml)
(week 6, p = 0.002; week 12, p = 0.001). The mean ApoB
level was 104 ± 13 and 90 ± 12 mg/dl at weeks 6 and 12,
respectively, showing no significant difference from baseline
(99 ± 9 mg/dl).
Safety evaluation
The safety was evaluated in 10 male subjects who ingested
the test food.
Laboratory parameters. The changes in the laboratory
parameters other than serum lipids over time are shown in
Tables 7 and 8. There was no change indicative of an adverse
event in any subject. The mean blood urea nitrogen level
was significantly increased at week 12 (baseline, 11.6 mg/dl;
week 12, 12.9 mg/dl), and the mean Na level was signifi-
cantly increased at weeks 6 and 12 (baseline, 141 mEq/l;
week 6, 143 mEq/L; week 12, 143 Eq/l). However, all of
these were slight changes within the reference range, with
no clinical significance.
Adverse events. A list of reported events is presented in
Table 9. A total of 5 events were reported in 2 subjects: soft
stools, nasal congestion/headache, myalgia, pharyngeal
pain/cough, and fever (1 event each). All of these events
were mild in severity and considered by the investigator to
be unrelated to the test food.
Discussion
Elevation of serum TG, like elevated LDL-cholesterol
level, is a risk factor for arteriosclerosis [16]. Hyper-
triglyceridemia may be attributed to excessively elevated
serum VLDL level, which occurs because of increased
VLDL synthesis and decreased lipoprotein lipase, a process
that degrades VLDL to LDL (abnormal metabolism of
VLDL) [17].
We previously investigated the metabolic effects of DNJ-
enriched mulberry extract for the prevention of diabetes
[11, 12]. In rats, administration of DNJ strongly attenuated
lipid accumulation through β-oxidation, which was pro-
moted by increased serum adiponectin level and activation
of AMP-activated protein kinase (AMPK) [12]. We
therefore conducted the present study to evaluate the effects
of DNJ in humans with high serum TG level.
We found that serum TG level was decreased in 7 of 9
subjects at week 12 following administration of DNJ. Mean
serum TG level was decreased by 43 mg/dl at week 6, and
by 60 mg/dl at week 12 (Table 2). In two subjects, serum
TG level was decreased below 150 mg/dl, the upper limit
of the reference range. Overall, there were no significant
differences at week 12 when compared to baseline. The lack
of statistical significance may have been attributed to
markedly increased serum TG level in two other subjects.
Future studies with larger sample sizes are required to
confirm the effects of DNJ on serum TG level in humans.
Mean CM-TG level, which reflects the transport of
exogenous lipids (primarily derived from food), was 50%
lower at week 12, when compared to baseline. Mean VLDL-
TG level, which reflects the transport of endogenous
lipids, was transiently higher at week 6, but did not differ
significantly from baseline at week 12 (Table 3). Since
blood samples were collected after restricting intake of
high-fat foods in the day preceding the blood test, and after
Table 6. Changes in adiponectin, leptin, and ApoB over time
Mean ± SD (n = 9). ** p<0.01, compared with week 0.
Parameter Unit
Baseline 
(Week 0)
Week 6 Week 12
Adiponectin μg/ml 6.3 ± 2.1 4.9 ± 1.5** 4.6 ± 1.4**
Leptin ng/ml 6.3 ± 4.1 5.2 ± 3.9** 4.7 ± 4.4**
ApoB mg/dl 99 ± 91 0 4 ± 13 90 ± 12
Table 7. Hematologic tests
Mean ± SD (n = 10). No significant difference was observed, compared with week 0.
Parameter Reference range Unit
Baseline 
(Week 0)
Week 6 Week 12
White blood cell count 3.9~9.8 103/μl5 . 8 ± 1.1 6.3 ± 1.7 6.2 ± 2.3
Red blood cell count 431~565 104/μl 506 ± 38 505 ± 23 501 ± 21
Hemoglobin 13.7~17.4 g/dl 15.6 ± 1.0 15.4 ± 0.6 15.5 ± 0.7
Hematocrit 40.2~51.5 % 45.5 ± 2.7 45.3 ± 2.1 45.2 ± 1.9
Platelet count 13.4~34.9 104/μl 26.1 ± 5.1 25.5 ± 5.8 25.6 ± 4.7Y. Kojima et al.
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a 12 h fast, serum chylomicron level was not significantly
confounded by foods ingested within the past two days.
No significant differences were seen for cholesterol level
at week 12. We assessed changes in serum lipoprotein
levels and size of lipoprotein particles. LDL, derived from
VLDL, is commonly referred to as “bad cholesterol”, because
excess LDL-cholesterol in blood results in vascular
cholesterol deposition. Smaller, or very-low-density LDL
particles (small and very small LDL fractions) are called
“very bad cholesterol” because they are often oxidized and
frequently induce adverse effects, including atherosclerosis.
Administration of DNJ resulted in a significant decrease in
very-small LDL fraction and a significant increase in
medium LDL fraction (Table 4). Although we observed a
significant increase in small LDL fraction, the increase
was modest after small LDL fraction was normalized by
the total of the four LDL subfractions; which increased by
15–17% at week 12 following administration of DNJ-rich
mulberry leaf extract.
Thus, based on percentage distribution, we found that use
of DNJ-rich mulberry leaf extract increased medium LDL
fraction, and decreased very small LDL fraction. The mean
particle size of VLDL was significantly decreased, but mean
particle sizes of LDL and HDL were significantly increased
(Table 5). Recent studies have linked abnormalities in
LDL structure to risks of cardiovascular disease [18]. Our
findings suggest that use of DNJ-rich mulberry leaf extract
may be beneficial by improving plasma lipoprotein profile.
Adiponectin and leptin—hormones involved in stimulation
of fat burning, were significantly decreased (Table 6). It is
generally accepted that stimulation of fat burning improves
dyslipidemia. In the present study, changes seen in the
plasma lipid profiles of subjects who took DNJ-rich
mulberry leaf extract appeared to be uncorrelated with
changes in adiponectin and leptin levels.
In conclusion, use of DNJ-rich mulberry leaf extract
modestly decreased TG level after 12-week intake, although
the decrease was not statistically significant. DNJ-rich
Table 8. Blood biochemical tests
Mean ± SD (n =9 ) .  *  p<0.05, ** p<0.01, compared with week 0.
Parameter Reference range Unit
Baseline 
(Week 0)
Week 6 Week 12
Total bilirubin 0.3~1.2 mg/dl 0.8 ± 0.3 0.8 ± 0.3 0.9 ± 0.3
AST 10~40 U/l 30 ± 92 8 ± 11 29 ± 15
ALT 5~40 U/l 52 ± 29 49 ± 30 47 ± 37
LDH 115~245 U/l 184 ± 37 177 ± 35 184 ± 40
ALP 115~359 U/l 175 ± 32 173 ± 33 168 ± 32
γ-GTP ≤70 U/l 63 ± 15 60 ± 26 59 ± 32
Total protein 6.7~8.3 g/dl 7.6 ± 0.4 7.6 ± 0.4 7.6 ± 0.3
Albumin 4.0~5.0 g/dl 4.6 ± 0.1 4.7 ± 0.2 4.7 ± 0.1
Creatinine 0.61~1.04 mg/dl 0.82 ± 0.12 0.81 ± 0.11 0.84 ± 0.12
Blood urea nitrogen 7.4~19.5 mg/dl 11.6 ± 2.6 12.9 ± 3.3 12.9 ± 3.4*
Fasting blood glucose 70~109 mg/dl 89 ± 58 7 ± 68 6 ± 6
HbA1c 4.3~5.8 % 5.2 ± 0.3 5.1 ± 0.3 5.1 ± 0.2
Insulin 1.79~10.4 μIU/ml 8.67 ± 6.56 8.31 ± 4.48 5.91 ± 1.73
Na 136~147 mEq/l 141 ± 2 143 ± 2** 143 ± 2*
K 3.6~5.0 mEq/l 4.4 ± 0.3 4.5 ± 0.3 4.3 ± 0.2
Cl 98~109 mEq/l 103 ± 2 103 ± 1 104 ± 2
Table 9. List of events reported
Subject No. Symptom Time of onset Time of resolution Causality
5133 Soft stools Day 30 Day 30 No
5152 Nasal congestion/headache Day 8 Day 38 No
Myalgia Day 43 Day 44 No
Pharyngeal pain/cough Day 57 Day 60 No
Fever Day 71 Day 72 NoBlood Lipid Profiles after Mulberry Leaf Extract Intake
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mulberry leaf extract may be potentially used to decrease
very bad cholesterol. Additional studies with larger sample
sizes are warranted. In terms of the safety of oral DNJ-rich
mulberry leaf extract, there were changes in some laboratory
parameters in the long-term treatment study. No clinically
significant changes in laboratory parameters were seen
during the study; there were also no reports of subjective
symptoms or adverse events related to use of DNJ-rich
mulberry leaf extract. Our findings confirm that short-term
use of DNJ-rich mulberry leaf extract is safe.
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